Wednesday, April 26, 2017 10:18:09 AM
Yes, additional human trials are needed, for several reasons. A conventional double-blind Phase 3 study, with an experimental arm (with the real Anavex 2-72), and a control arm, where a physically identical placebo is administered is needed. FDA rules require such for eventual drug approval. FDA is “protecting us.” They want to be as certain as possible that adverse events (side effects) are minimal and not disqualifying, and that the drug actually works, with regulatory efficacy. The previous Phase 1/Phase 2 study is inadequate for all of this — a matter I do not contest in any way.
My point is this. The existing murine and P1/P2 data, coupled with an understanding of how Anavex 2-73 restores normalized neuron function (its hard cellular biochemistry) all predict a very successful Phase 3 trial. The chances that the drug will prove non-effective in stabilizing or reducing Alzheimer’s symptoms, and/or prove to have disqualifying adverse events are, to me, infinitesimally tiny. Hence, I’m confident in the appreciating value of my early equity position in AVXL. Wish I could buy more shares.
You mentioned the heretofore unconsidered factors of insomnia relief and quality of life outcomes for both patients and care givers. I would add the many additional conditions Anavex pipeline drugs will treat; from cancers, psychiatric conditions, heart disease, to epilepsy, and a growing number of others. All of that will play out so favorably in coming years, for both patients and Anavex Life Sciences, I’m certain.
The magnitude of the Anavex medical revolution is unappreciated by most. Few are able to envision it, for several reasons. Commonly, Anavex’s Alzheimer’s approach is erroneously conflated and mixed with the dozens of failed amyloid suppression or removal trials of other drug companies. They all fail; therefore, Anavex 2-73 is likewise destined for expensive clinical failures, too.
Many others fail to understand Anavex 2-73's unique biochemistry and its ability to restore normal cell function. Too good to be true. Appears to be a mystical nostrum. Can’t be true, as future clinical trials will prove (so they think).
Then, Anavex Life Sciences is a pharmaceutical start-up, with no proven revenues, without even an FDA-approved product. The record for such companies mandates a very harsh assessment regarding any retail equity position. Therefore, it’s regarded as a long and potentially bad gamble by so many “experts,” both financial and scientific.
You mentioned the assessment of a placebo effect as a potential cause of clinical efficacy. Not a factor. Not a consideration. No one, ever, has been able to suppress or reverse the multitude of Alzheimer’s symptoms by willful or hopeful thinking.
Anavex Life Sciences and Anavex 2-73 are the real things.
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM